Reference(s)
Click here to return to the Reference Table

Category: Carcinomas
Cancer type: Lung
Descriptor: Therapeutic Development


Reference Number: 23
Kuba, K. et al. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res 60, 6737-43 (2000).
PubMed link      E-mail link

Reference Number: 38
Fazekas, K., Raso, E., Zarandi, M., Dudas, J. & Timar, J. Basic HGF-like peptides inhibit generation of liver metastases in murine and human tumor models. Anticancer Res 22, 2575-9 (2002).
PubMed link      E-mail link

Reference Number: 244
Stabile LP, Lyker JS, Huang L, Siegfried JM. Inhibition of human non-small cell lung tumors by a c-Met antisense/U6 expression plasmid strategy. Gene Ther 11:325-35 (2004).
PubMed link      E-mail link

Reference Number: 275
Tokunou M, Niki T, Eguchi K, Iba S, Tsuda H, Yamada T, Matsuno Y, Kondo H, Saitoh Y, Imamura H, Hirohashi S.  c-MET expression in myofibroblasts: role in autocrine activation and prognostic significance in lung adenocarcinoma.  Am J Pathol 1581451-63 (2001).
PubMed link      E-mail link

Reference Number: 298
Kushibiki T, Matsumoto K, Nakamura T, Tabata Y. Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther 11, 1205-14 (2004)
PubMed link      E-mail link

Reference Number: 333
Ma PC, Jagadeeswaran R, Jagadeesh S, Tretiakova MS, Nallasura V, Fox EA, Hansen M, Schaefer E, Naoki K, Lader A, Richards W, Sugarbaker D, Husain AN, Christensen JG, Salgia R. Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res65, 1479-88 (2005)
PubMed link      E-mail link

Reference Number: 337
Ma PC, Schaefer E, Christensen JG, Salgia R. A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin. Clin Cancer Res. 11, 2312-9 (2005)
PubMed link      E-mail link

Reference Number: 342
Mazzone M, Basilico C, Cavassa S, Pennacchietti S, Risio M, Naldini L, Comoglio PM, Michieli P. An uncleavable form of pro-scatter factor suppresses tumor growth and dissemination in mice. J Clin Invest. 114, 1418-32 (2004)
PubMed link      E-mail link

Reference Number: 569
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J, Kosaka T, Holmes AJ, Rogers AM, Cappuzzo F, Mok T, Lee C, Johnson BE, Cantley LC, Jänne PA. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 316, 1039-43 (2007)
PubMed link      E-mail link

Reference Number: 571
Puri N, Khramtsov A, Ahmed S, Nallasura V, Hetzel JT, Jagadeeswaran R, Karczmar G, Salgia R. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 67, 3529-34 (2007)
PubMed link      E-mail link

Reference Number: 641
Beau-Faller M, Ruppert AM, Voegeli AC, Neuville A, Meyer N, Guerin E, Legrain M, Mennecier B, Wihlm JM, Massard G, Quoix E, Oudet P, Gaub MP. MET gene copy number in non-small cell lung cancer: molecular analysis in a targeted tyrosine kinase inhibitor naïve cohort. J Thorac Oncol. 3, 331-9 (2008)
PubMed link      E-mail link

Reference Number: 656
Stabile LP, Rothstein ME, Keohavong P, Jin J, Yin J, Land SR, Dacic S, Luong TM, Kim KJ, Dulak AM, Siegfried JM. Therapeutic targeting of human hepatocyte growth factor with a single neutralizing monoclonal antibody reduces lung tumorigenesis. Mol Cancer Ther. 7, 1913-22 (2008)
PubMed link      E-mail link

Reference Number: 692
Yano S, Wang W, Li Q, Matsumoto K, Sakurama H, Nakamura T, Ogino H, Kakiuchi S, Hanibuchi M, Nishioka Y, Uehara H, Mitsudomi T, Yatabe Y, Nakamura T, Sone S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 68, 9479-87 (2008)
PubMed link      E-mail link

Reference Number: 700
Tang Z, Du R, Jiang S, Wu C, Barkauskas DS, Richey J, Molter J, Lam M, Flask C, Gerson S, Dowlati A, Liu L, Lee Z, Halmos B, Wang Y, Kern JA, Ma PC. Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer. 99, 911-22  (2008)
PubMed link      E-mail link

Reference Number: 704
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S, Balak M, Chang WC, Yu CJ, Gazdar A, Pass H, Rusch V, Gerald W, Huang SF, Yang PC, Miller V, Ladanyi M, Yang CH, Pao W. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci U S A. 104, 20932-7 (2007) Epub 2007 Dec 18
PubMed link      E-mail link

Reference Number: 714
Cappuzzo F, Jänne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, Zucali PA, Terracciano L, Toschi L, Roncalli M, Destro A, Incarbone M, Alloisio M, Santoro A, Varella-Garcia M. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol. 20, 298-304 (2009) Epub 2008 Oct 3
PubMed link      E-mail link

Reference Number: 725
Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer. 63, 169-79. Epub 2008 Jul 30 (2009)
PubMed link      E-mail link

Reference Number: 798
Wang X, Li K, Chen H, Wang D, Zhang Y, Bai C. Does hepatocyte growth factor/c-Met signal play synergetic role in lung cancer? J Cell Mol Med. 14, 833-9 (2010)
PubMed link      E-mail link

Reference Number: 838
Bagai R, Fan W, Ma PC. ARQ-197, an oral small-molecule inhibitor of c-Met for the treatment of solid tumors. IDrugs. 13, 404-14 (2010)
PubMed link      E-mail link

Reference Number: 911
Matsubara D, Ishikawa S, Oguni S, Aburatani H, Fukayama M, Niki T. Molecular predictors of sensitivity to the MET inhibitor PHA665752 in lung carcinoma cells. J Thorac Oncol. 5, 1317-24 (2010)
PubMed link      E-mail link

Reference Number: 912
Nakachi I, Naoki K, Soejima K, Kawada I, Watanabe H, Yasuda H, Nakayama S, Yoda S, Satomi R, Ikemura S, Terai H, Sato T, Ishizaka A. The combination of multiple receptor tyrosine kinase inhibitor and mammalian target of rapamycin inhibitor overcomes erlotinib resistance in lung cancer cell lines through c-Met inhibition. Mol Cancer Res. 8, 1142-51 (2010)
PubMed link      E-mail link

Reference Number: 939
Matsubara D, Ishikawa S, Sachiko O, Aburatani H, Fukayama M, Niki T. Co-activation of epidermal growth factor receptor and c-MET defines a distinct subset of lung adenocarcinomas. Am J Pathol. 177, 2191-204 (2010)
PubMed link      E-mail link

Reference Number: 950
Onitsuka T, Uramoto H, Nose N, Takenoyama M, Hanagiri T, Sugio K, Yasumoto K. Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. Lung Cancer. 68, 198-203 (2010
PubMed link      E-mail link

Reference Number: 951
Milligan SA, Burke P, Coleman DT, Bigelow RL, Steffan JJ, Carroll JL, Williams BJ, Cardelli JA. The green tea polyphenol EGCG potentiates the antiproliferative activity of c-Met and epidermal growth factor receptor inhibitors in non-small cell lung cancer cells. Clin Cancer Res. 15, 4885-94 (2009)
PubMed link      E-mail link

Reference Number: 959
Eathiraj S, Palma R, Volckova E, Hirschi M, France DS, Ashwell MA, Chan TC. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197. J Biol Chem. 286, 20666-76 (2011)
PubMed link      E-mail link

Reference Number: 965
Zhang YW, Staal B, Essenburg C, Su Y, Kang L, West R, Kaufman D, Dekoning T, Eagleson B, Buchanan SG, Vande Woude GF. MET kinase inhibitor SGX523 synergizes with epidermal growth factor receptor inhibitor erlotinib in a hepatocyte growth factor-dependent fashion to suppress carcinoma growth. Cancer Res. 70, 6880-90 (2010)
PubMed link      E-mail link

Reference Number: 969
Yamada T, Matsumoto K, Wang W, Li Q, Nishioka Y, Sekido Y, Sone S, Yano S. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Clin Cancer Res. 16, 174-83 (2010)
PubMed link      E-mail link

Reference Number: 977
Dulak AM, Gubish CT, Stabile LP, Henry C, Siegfried JM. HGF-independent potentiation of EGFR action by c-Met. Oncogene. 30, 3625-35 (2011)
PubMed link      E-mail link

Reference Number: 993

Salgia R, Hensing T, Campbell N, Salama AK, Maitland M, Hoffman P, Villaflor V, Vokes EE. Personalized treatment of lung cancer. Semin Oncol. 38, 274-83 (2011)
PubMed link      E-mail link

Reference Number: 996
Lu RM, Chang YL, Chen MS, Wu HC. Single chain anti-c-Met antibody conjugated nanoparticles for in vivo tumor-targeted imaging and drug delivery. Biomaterials. 32, 3265-74 (2011)
PubMed link      E-mail link

Reference Number: 1002
Colon J, Basha MR, Madero-Visbal R, Konduri S, Baker CH, Herrera LJ, Safe S, Sheikh-Hamad D, Abudayyeh A, Alvarado B, Abdelrahim M. Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice. Invest New Drugs. 29, 41-51 (2011)
PubMed link      E-mail link

Reference Number: 1028
Wang ZX, Lu BB, Yang JS, Wang KM, De W. Adenovirus-mediated siRNA targeting c-Met inhibits proliferation and invasion of small-cell lung cancer (SCLC) cells. J Surg Res. 171, 127-35 (2011)
PubMed link      E-mail link

Reference Number: 1030
Tanizaki J, Okamoto I, Okamoto K, Takezawa K, Kuwata K, Yamaguchi H, Nakagawa K. MET tyrosine kinase inhibitor crizotinib (PF-02341066) shows differential antitumor effects in non-small cell lung cancer according to MET alterations. J Thorac Oncol. 6, 1624-31 (2011)
PubMed link      E-mail link

Reference Number: 1052
Arriola E, Cañadas I, Arumí-Uría M, Dómine M, Lopez-Vilariño JA, Arpí O, Salido M, Menéndez S, Grande E, Hirsch FR, Serrano S, Bellosillo B, Rojo F, Rovira A, Albanell J. MET phosphorylation predicts poor outcome in small cell lung carcinoma and its inhibition blocks HGF-induced effects in MET mutant cell lines. Br J Cancer. 105, 814-23 (2011)
PubMed link      E-mail link

Reference Number: 1053
Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, Chen Y, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol. 29, 3307-15 (2011)
PubMed link      E-mail link

Reference Number: 1064
Garofalo M, Romano G, Di Leva G, Nuovo G, Jeon YJ, Ngankeu A, Sun J, Lovat F, Alder H, Condorelli G, Engelman JA, Ono M, Rho JK, Cascione L, Volinia S, Nephew KP, Croce CM. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 18, 74-82 (2011)
PubMed link      E-mail link

Reference Number: 1069
Milanovic M, Radtke S, Peel N, Howell M, Carrière V, Joffre C, Kermorgant S, Parker PJ. Anomalous inhibition of c-Met by the kinesin inhibitor aurintricarboxylic acid. Int J Cancer. 130, 1060-70 (2012)
PubMed link      E-mail link

Reference Number: 1074
Donev IS, Wang W, Yamada T, Li Q, Takeuchi S, Matsumoto K, Yamori T, Nishioka Y, Sone S, Yano S. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Clin Cancer Res. 17, 2260-9 (2011)
PubMed link      E-mail link

Reference Number: 1078
Lawrence RE, Salgia R. MET molecular mechanisms and therapies in lung cancer. Cell Adh Migr. 4, 146-52 (2010)
PubMed link      E-mail link

Reference Number: 1083
Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, Yano S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res. 15, 6630-8 (2009)
PubMed link      E-mail link

Reference Number: 1094
Kanteti R, Nallasura V, Loganathan S, Tretiakova M, Kroll T, Krishnaswamy S, Faoro L, Cagle P, Husain AN, Vokes EE, Lang D, Salgia R. PAX5 is expressed in small-cell lung cancer and positively regulates c-Met transcription. Lab Invest. 89, 301-14 (2009)
PubMed link      E-mail link

Reference Number: 1099
Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, Camidge DR, Solomon BJ, Maki RG, Bang YJ, Kim DW, Christensen J, Tan W, Wilner KD, Salgia R, Iafrate AJ. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol. 6, 942-6 (2011)
PubMed link      E-mail link

Reference Number: 1103
Surati M, Patel P, Peterson A, Salgia R. Role of MetMAb (OA-5D5) in c-MET active lung malignancies. Expert Opin Biol Ther. 11, 1655-62 (2011)
PubMed link      E-mail link

Reference Number: 1104
Han JY, Kim JY, Lee SH, Yoo NJ, Choi BG. Association between plasma hepatocyte growth factor and gefitinib resistance in patients with advanced non-small cell lung cancer. Lung Cancer. 74, 293-9 (2011)
PubMed link      E-mail link

Reference Number: 1134
Yamada T, Takeuchi S, Kita K, Bando H, Nakamura T, Matsumoto K, Yano S. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. J Thorac Oncol. 7, 272-80 (2012)
PubMed link      E-mail link

Reference Number: 1135
Feng Y, Thiagarajan PS, Ma PC. MET signaling: novel targeted inhibition and its clinical development in lung cancer. J Thorac Oncol. 7, 459-67 (2012)
PubMed link      E-mail link

Reference Number: 1158
Shojaei F, Simmons BH, Lee JH, Lappin PB, Christensen JG. HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis. Cancer Lett. 320, 48-55 (2012)
PubMed link      E-mail link

Reference Number: 1159
Han SY, Lee CO, Ahn SH, Lee MO, Kang SY, Cha HJ, Cho SY, Ha JD, Ryu JW, Jung H, Kim HR, Koh JS, Lee J. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs. 30, 518-23 (2012)
PubMed link      E-mail link

Reference Number: 1224
Bhardwaj V, Zhan Y, Cortez MA, Ang KK, Molkentine D, Munshi A, Raju U, Komaki R, Heymach JV, Welsh J. C-Met inhibitor MK-8003 radiosensitizes c-Met-expressing non-small-cell lung cancer cells with radiation-induced c-Met-expression. J Thorac Oncol. 7, 1211-7 (2012)
PubMed link      E-mail link

Reference Number: 1229
Liu Y, Yang Y, Ye YC, Shi QF, Chai K, Tashiro S, Onodera S, Ikejima T. Activation of ERK-p53 and ERK-mediated phosphorylation of Bcl-2 are involved in autophagic cell death induced by the c-Met inhibitor SU11274 in human lung cancer A549 cells. J Pharmacol Sci. 118, 423-32 (2012)
PubMed link      E-mail link

Reference Number: 1230
Yang M, Shan B, Li Q, Song X, Cai J, Deng J, Zhang L, Du Z, Lu J, Chen T, Wery JP, Chen Y, Li Q. Overcoming erlotinib resistance with tailored treatment regimen in patient-derived xenografts from naïve Asian NSCLC patients. Int J Cancer. 132, E74-84 (2013)
PubMed link      E-mail link

Reference Number: 1235
Yamada T, Takeuchi S, Nakade J, Kita K, Nakagawa T, Nanjo S, Nakamura T, Matsumoto K, Soda M, Mano H, Uenaka T, Yano S. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Clin Cancer Res. 18, 3592-602 (2012)
PubMed link      E-mail link

Reference Number: 1237
Zhang Z, Lee JC, Lin L, Olivas V, Au V, LaFramboise T, Abdel-Rahman M, Wang X, Levine AD, Rho JK, Choi YJ, Choi CM, Kim SW, Jang SJ, Park YS, Kim WS, Lee DH, Lee JS, Miller VA, Arcila M, Ladanyi M, Moonsamy P, Sawyers C, Boggon TJ, Ma PC, Costa C, Taron M, Rosell R, Halmos B, Bivona TG. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 44, 852-60 (2012)
PubMed link      E-mail link

Reference Number: 1264
Petrelli F, Borgonovo K, Cabiddu M, Ghilardi M, Barni S. Biological agents alone or in combination as second-line therapy in advanced non-small-cell lung cancer: systematic review of randomized studies. Expert Rev Anticancer Ther. 12, 1299-312 (2012)
PubMed link      E-mail link

Reference Number: 1265
Yano S, Takeuchi S, Nakagawa T, Yamada T. Ligand-triggered resistance to molecular targeted drugs in lung cancer: roles of hepatocyte growth factor and epidermal growth factor receptor ligands. Cancer Sci. 103, 1189-94 (2012)
PubMed link      E-mail link

Reference Number: 1279
Bang YJ. Treatment of ALK-positive non-small cell lung cancer. Arch Pathol Lab Med. 136, 1201-4 (2012)
PubMed link      E-mail link

Reference Number: 1281
Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, Sone S, Nakagawa T, Uenaka T, Yano S. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol. 181, 1034-43 (2012)
PubMed link      E-mail link

Reference Number: 1289
Voortman J, Harada T, Chang RP, Killian JK, Suuriniemi M, Smith WI, Meltzer PS, Lucchi M, Wang Y, Giaccone G. Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors. Curr Pharm Des. 19, 833-40 (2013)
PubMed link      E-mail link

Reference Number: 1291
Nakagawa T, Takeuchi S, Yamada T, Nanjo S, Ishikawa D, Sano T, Kita K, Nakamura T, Matsumoto K, Suda K, Mitsudomi T, Sekido Y, Uenaka T, Yano S. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Mol Cancer Ther. 11, 2149-57 (2012)
PubMed link      E-mail link

Reference Number: 1293
Michikoshi H, Nakamura T, Sakai K, Suzuki Y, Adachi E, Matsugo S, Matsumoto K. a-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells. Cancer Lett. 335, 472-8 (2013)
PubMed link      E-mail link

Reference Number: 1294
Landi L, Minuti G, D'Incecco A, Cappuzzo F. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer. Curr Opin Oncol. 25, 130-6 (2013)
PubMed link      E-mail link

Reference Number: 1301
Ou SH, Bartlett CH, Mino-Kenudson M, Cui J, Iafrate AJ. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist. 17, 1351-75 (2012)
PubMed link      E-mail link

Reference Number: 1310
Sano T, Takeuchi S, Nakagawa T, Ishikawa D, Nanjo S, Yamada T, Nakamura T, Matsumoto K, Yano S. The novel phosphoinositide 3-kinase-mammalian target of rapamycin inhibitor, BEZ235, circumvents erlotinib resistance of epidermal growth factor receptor mutant lung cancer cells triggered by hepatocyte growth factor. Int J Cancer. 133, 505-13 (2013)
PubMed link      E-mail link

Reference Number: 1342
Ogi S1, Fujita H, Kashihara M, Yamamoto C, Sonoda K, Okamoto I, Nakagawa K, Ohdo S, Tanaka Y, Kuwano M, Ono M. Sorting nexin 2-mediated membrane trafficking of c-Met contributes to sensitivity of molecular-targeted drugs. Cancer Sci. 104(5):573-83 (2013)
PubMed link      E-mail link

Reference Number: 1366
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1375
Wang J, Pursell NW, Samson ME, Atoyan R, Ma AW, Selmi A, Xu W, Cai X, Voi M, Savagner P, Lai CJ. Potential advantages of CUDC-101, a multitargeted HDAC, EGFR, and HER2 inhibitor, in treating drug resistance and preventing cancer cell migration and invasion. Mol Cancer Ther. 12, 925-36 (2013)
PubMed link      E-mail link

Reference Number: 1402
Casaluce F1, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Target Oncol. 8, 55-67 (2013)
PubMed link      E-mail link

Reference Number: 1403
Chen G1, Noor A, Kronenberger P, Teugels E, Umelo IA, De Grève J. Synergistic effect of afatinib with su11274 in non-small cell lung cancer cells resistant to gefitinib or erlotinib. PLoS One. 8, e59708 (2013)
PubMed link      E-mail link

Reference Number: 1412
Timm A1, Kolesar JM. Crizotinib for the treatment of non-small-cell lung cancer. Am J Health Syst Pharm. 70, 943-7 (2013)
PubMed link      E-mail link

Reference Number: 1433
Roskoski R Jr. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders. Expert Opin Drug Discov. 8, 1165-79 (2013)
PubMed link      E-mail link

Reference Number: 1439
Zhang YW1, Staal B, Essenburg C, Lewis S, Kaufman D, Vande Woude GF. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR. Mol Cancer Ther. 12, 1429-41 (2013)
PubMed link      E-mail link

Reference Number: 1444
Penuel E1, Li C, Parab V, Burton L, Cowan KJ, Merchant M, Yauch RL, Patel P, Peterson A, Hampton GM, Lackner MR, Hegde PS. HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumors. Mol Cancer Ther. 12, 1122-30 (2013)
PubMed link      E-mail link

Reference Number: 1461
Yamamoto N1, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa K. CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer. Br J Cancer. 109, 2803-9 (2013)
PubMed link      E-mail link

Reference Number: 1464
Kawada I, Hasina R, Arif Q, Mueller J, Smithberger E, Husain AN, Vokes EE, Salgia R. Dramatic antitumor effects of the dual MET/RON small-molecule inhibitor LY2801653 in non-small cell lung cancer. Cancer Res. 74, 884-95 (2014)
PubMed link      E-mail link

Reference Number: 1473
Tumati V, Kumar S, Yu L, Chen B, Choy H, Saha D. Effect of PF-02341066 and radiation on non-small cell lung cancer cells. Oncol Rep. 29, 1094-100 (2013)
PubMed link      E-mail link

Reference Number: 1485
Jang WJ, Jung SK, Kang JS, Jeong JW, Bae MK, Joo SH, Park GH, Kundu JK, Hong YS, Jeong CH. Cancer Sci. Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in gefitinib-resistant non-small cell lung cancers with Met amplification. Cancer Sci 105, 1245-53 (2014)
PubMed link      E-mail link

Reference Number: 1506
Ishikawa D, Takeuchi S, Nakagawa T, Sano T, Nakade J, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Nakamura T, Matsumoto K, Kagamu H, Yoshizawa H, Yano S. mTOR inhibitors control the growth of EGFR mutant lung cancer even after acquiring resistance by HGF. PLoS One. 8, e62104 (2013)
PubMed link      E-mail link

Reference Number: 1508
Li B, Torossian A, Sun Y, Du R, Dicker AP, Lu B. Higher levels of c-Met expression and phosphorylation identify cell lines with increased sensitivity to AMG-458, a novel selective c-Met inhibitor with radiosensitizing effects. Int J Radiat Oncol Biol Phys. 84, e525-31 (2012)
PubMed link      E-mail link

Reference Number: 1509
Koudelakova V, Kneblova M, Trojanec R, Drabek J, Hajduch M. Non-small cell lung cancer--genetic predictors. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 157, 125-36 (2013)
PubMed link      E-mail link

Reference Number: 1512
La Monica S, Caffarra C, Saccani F, Galvani E, Galetti M, Fumarola C, Bonelli M, Cavazzoni A, Cretella D, Sirangelo R, Gatti R, Tiseo M, Ardizzoni A, Giovannetti E, Petronini PG, Alfieri RR. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification. PLoS One. 8, e78656 (2013)
PubMed link      E-mail link

Reference Number: 1515
Chen X, Zhou JY, Zhao J, Chen JJ, Ma SN, Zhou JY. Crizotinib overcomes hepatocyte growth factor-mediated resistance to gefitinib in EGFR-mutant non-small-cell lung cancer cells. Anticancer Drugs. 24, 1039-46 (2013)
PubMed link      E-mail link

Reference Number: 1536
Schwab R, Petak I, Kollar M, Pinter F, Varkondi E, Kohanka A, Barti-Juhasz H, Schönleber J, Brauswetter D, Kopper L, Urban L. Major partial response to crizotinib, a dual MET/ALK inhibitor, in a squamous cell lung (SCC) carcinoma patient with de novo c-MET amplification in the absence of ALK rearrangement. Lung Cancer. 83, 109-11 (2014)
PubMed link      E-mail link

Reference Number: 1540
Stutz E, Gautschi O, Fey MF, Gugger M, Tschan MP, Rothschild SI. Crizotinib inhibits migration and expression of ID1 in MET-positive lung cancer cells: implications for MET targeting in oncology. Future Oncol. 10, 211-7 (2014)
PubMed link      E-mail link

Reference Number: 1575
Zhou YM, Liu J, Sun W. MiR-130a overcomes gefitinib resistance by targeting met in non-small cell lung cancer cell lines. Asian Pac J Cancer Prev. 15, 1391-6 (2014)
PubMed link      E-mail link

Reference Number: 1579
Ozasa H, Oguri T, Maeno K, Takakuwa O, Kunii E, Yagi Y, Uemura T, Kasai D, Miyazaki M, Niimi A. Significance of c-MET overexpression in cytotoxic anticancer drug-resistant small-cell lung cancer cells. Cancer Sci. 105, 1032-9 (2014)
PubMed link      E-mail link

Reference Number: 1598
Yang X, Yang Y, Tang S, Tang H, Yang G, Xu Q, Wu J. Anti-tumor effect of polysaccharides from Scutellaria barbata D. Don on the 95-D xenograft model via inhibition of the C-met pathway. J Pharmacol Sci. 125, 255-63 (201)
PubMed link      E-mail link

Reference Number: 1599
Nanjo S, Yamada T, Nishihara H, Takeuchi S, Sano T, Nakagawa T, Ishikawa D, Zhao L, Ebi H, Yasumoto K, Matsumoto K, Yano S Ability of the Met kinase inhibitor crizotinib and new generation EGFR inhibitors to overcome resistance to EGFR inhibitors. PLoS One. 8, e84700 (2013)
PubMed link      E-mail link

Reference Number: 1615
Liao ZJ, Guo YH, Zhao Z, Yao JT, Xu R, Nan KJ. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway. Int J Oncol. 45, 651-8 (2014)
PubMed link      E-mail link

Reference Number: 1618
Qu G, Liu C, Sun B, Zhou C, Zhang Z, Wang P. Combination of BIBW2992 and ARQ 197 is effective against erlotinib-resistant human lung cancer cells with the EGFR T790M mutation. Oncol Rep. 32, 341-7 (2014)
PubMed link      E-mail link

Reference Number: 1619
Nakade J, Takeuchi S, Nakagawa T, Ishikawa D, Sano T, Nanjo S, Yamada T, Ebi H, Zhao L, Yasumoto K, Matsumoto K, Yonekura K, Yano S. Triple inhibition of EGFR, Met, and VEGF suppresses regrowth of HGF-triggered, erlotinib-resistant lung cancer harboring an EGFR mutation. J Thorac Oncol. 9, 775-83 (2014)
PubMed link      E-mail link

Reference Number: 1670
Matsumoto Y, Maemondo M, Ishii Y, Okudera K, Demura Y, Takamura K, Kobayashi K, Morikawa N, Gemma A, Ishimoto O, Usui K, Harada M, Miura S, Fujita Y, Sato I, Saijo Y; North-East Japan Study Group. A phase II study of erlotinib monotherapy in pre-treated non-small cell lung cancer without EGFR gene mutation who have never/light smoking history: re-evaluation of EGFR gene status (NEJ006/TCOG0903). Lung Cancer. 86, 195-200 (2014)
PubMed link      E-mail link

Reference Number: 1671
Koeppen H, Yu W, Zha J, Pandita A, Penuel E, Rangell L, Raja R, Mohan S, Patel R, Desai R, Fu L, Do A, Parab V, Xia X, Januario T, Louie SG, Filvaroff E, Shames DS, Wistuba I, Lipkind M, Huang J, Lazarov M, Ramakrishnan V, Amler L, Phan SC, Patel P, Peterson A, Yauch RL. Biomarker analyses from a placebo-controlled phase II study evaluating erlotinib±onartuzumab in advanced non-small cell lung cancer: MET expression levels are predictive of patient benefit. Clin Cancer Res. 20, 4488-98 (2014)
PubMed link      E-mail link

Reference Number: 1675
Iommelli F, De Rosa V, Gargiulo S, Panico M, Monti M, Greco A, Gramanzini M, Ortosecco G, Fonti R, Brunetti A, Del Vecchio S. Monitoring reversal of MET-mediated resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer using 3'-deoxy-3'-[18F]-fluorothymidine positron emission tomography. Clin Cancer Res. 20, 4806-15 (2014)
PubMed link      E-mail link

Reference Number: 1677
Jang WJ, Park B, Jeong GS, Hong SS, Jeong CH. SB365, Pulsatilla saponin D, suppresses the growth of gefitinib-resistant NSCLC cells with Met amplification. Oncol Rep. 32, 2612-8 (2014)
PubMed link      E-mail link

Reference Number: 1679
Holland WS, Chinn DC, Lara PN Jr, Gandara DR, Mack PC. Effects of AKT inhibition on HGF-mediated erlotinib resistance in non-small cell lung cancer cell lines. J Cancer Res Clin Oncol. 141, 615-26 (2015)
PubMed link      E-mail link

Reference Number: 1705
Tanimoto A, Yamada T, Nanjo S, Takeuchi S, Ebi H, Kita K, Matsumoto K, Yano S. Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells. Oncotarget. 5, 4920-8 (2014)
PubMed link      E-mail link

Reference Number: 1706
Jung SK, Lee MH, Lim do Y, Lee SY, Jeong CH, Kim JE, Lim TG, Chen H, Bode AM, Lee HJ, Lee KW, Dong Z. Butein, a novel dual inhibitor of MET and EGFR, overcomes gefitinib-resistant lung cancer growth. Mol Carcinog. 54, 322-31 (2015)
PubMed link      E-mail link

Reference Number: 1707
Stabile LP, Rothstein ME, Gubish CT, Cunningham DE, Lee N, Siegfried JM. Co-targeting c-Met and COX-2 leads to enhanced inhibition of lung tumorigenesis in a murine model with heightened airway HGF. J Thorac Oncol. 9, 1285-93 (2014)
PubMed link      E-mail link

Reference Number: 1750
Yagishita S, Hamada A. Clinical pharmacology of EGFR/Met inhibitors in non-small cell lung cancer. Curr Drug Targets. 15, 1263-72 (2014)
PubMed link      E-mail link

Reference Number: 1777
Sano Y, Hashimoto E, Nakatani N, Abe M, Satoh Y, Sakata K, Fujii T, Fujimoto-Ouchi K, Sugimoto M, Nagahashi S, Aoki M, Motegi H, Sasaki E, Yatabe Y. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression. Mol Cancer Ther. 14, 533-41 (2015)
PubMed link      E-mail link

Reference Number: 1794
Paik PK, Drilon A, Fan PD, Yu H, Rekhtman N, Ginsberg MS, Borsu L, Schultz N, Berger MF, Rudin CM, Ladanyi M. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping. Cancer Discov. 5, 842-9 (2015)
PubMed link      E-mail link

Reference Number: 1798
Ahsan A Mechanisms of Resistance to EGFR Tyrosine Kinase Inhibitors and Therapeutic Approaches: An Update. Adv Exp Med Biol. 893, 137-53 (2016)
PubMed link      E-mail link

Reference Number: 1802
Sargis RM, Salgia R Multiple Endocrine Disruption by the MET/ALK Inhibitor Crizotinib in Patients With Non-small Cell Lung Cancer. Am J Clin Oncol. 38, 442-7 (2015)
PubMed link      E-mail link

Reference Number: 1814
Calles A, Kwiatkowski N, Cammarata BK, Ercan D, Gray NS, Jänne PA. Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines. Mol Oncol. 9, 260-9 (2015)
PubMed link      E-mail link

Reference Number: 1816
Nishio M, Horiike A, Nokihara H, Horinouchi H, Nakamichi S, Wakui H, Ohyanagi F, Kudo K, Yanagitani N, Takahashi S, Kuboki Y, Yamamoto N, Yamada Y, Abe M, Tahata T, Tamura T. Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Invest New Drugs. 33, 632-40 (2015)
PubMed link      E-mail link

Reference Number: 1817
Choi YJ, Kim SY, So KS, Baek IJ, Kim WS, Choi SH, Lee JC, Bivona TG, Rho JK, Choi CM. AUY922 effectively overcomes MET- and AXL-mediated resistance to EGFR-TKI in lung cancer cells. PLoS One. 10, e0119832 (2015)
PubMed link      E-mail link